ATE126438T1 - Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren. - Google Patents

Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren.

Info

Publication number
ATE126438T1
ATE126438T1 AT90112426T AT90112426T ATE126438T1 AT E126438 T1 ATE126438 T1 AT E126438T1 AT 90112426 T AT90112426 T AT 90112426T AT 90112426 T AT90112426 T AT 90112426T AT E126438 T1 ATE126438 T1 AT E126438T1
Authority
AT
Austria
Prior art keywords
salts
folic acid
leucovine
methods
pharmaceutical formulation
Prior art date
Application number
AT90112426T
Other languages
English (en)
Inventor
Bruce Edwin Haeger
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE126438T1 publication Critical patent/ATE126438T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT90112426T 1989-08-21 1990-06-29 Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren. ATE126438T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39657389A 1989-08-21 1989-08-21

Publications (1)

Publication Number Publication Date
ATE126438T1 true ATE126438T1 (de) 1995-09-15

Family

ID=23567787

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90112426T ATE126438T1 (de) 1989-08-21 1990-06-29 Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren.

Country Status (11)

Country Link
EP (1) EP0416232B1 (de)
JP (1) JP3043381B2 (de)
KR (1) KR0159768B1 (de)
AT (1) ATE126438T1 (de)
AU (1) AU628211B2 (de)
CA (1) CA2023563C (de)
DE (1) DE69021673T2 (de)
DK (1) DK0416232T3 (de)
ES (1) ES2076263T3 (de)
GR (1) GR3017143T3 (de)
PT (1) PT95026B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH684644A5 (de) 1992-07-13 1994-11-15 Eprova Ag 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
CH687062A5 (de) * 1994-02-14 1996-09-13 Cerbios Pharma Sa Konzentrierte Injektionsloesung von Alkalimetallsalzen von reduzierten Folaten.
AUPQ899400A0 (en) * 2000-07-26 2000-08-17 Csl Limited A method of stabilisation and compositions for use therein
JP4956942B2 (ja) * 2004-09-15 2012-06-20 ニプロ株式会社 安定化された注射用水溶液製剤
KR20060051135A (ko) * 2004-09-15 2006-05-19 니프로 가부시키가이샤 안정화된 주사용 수용액 제재
JP4545632B2 (ja) * 2005-04-25 2010-09-15 株式会社 伊藤園 葉酸含有組成物及び葉酸の安定化方法
JP4919024B2 (ja) * 2006-11-16 2012-04-18 横河電機株式会社 圧力センサ
JP4906546B2 (ja) * 2007-03-15 2012-03-28 株式会社ヤクルト本社 レボホリナート含有水溶液製剤
JP6057254B2 (ja) * 2013-01-23 2017-01-11 パナソニックＩｐマネジメント株式会社 赤外線受光ユニット、赤外線式ガスセンサ
WO2014112392A1 (ja) 2013-01-21 2014-07-24 パナソニック株式会社 赤外線検出素子、赤外線検出器及び赤外線式ガスセンサ
EP2799061A1 (de) 2013-04-30 2014-11-05 Aprofol AG Stabile pharmazeutische Hochdosiszusammensetzungen enthaltend Folate
EP2799060A1 (de) 2013-04-30 2014-11-05 Aprofol AG Stabile hochdosierte pharmazeutische Zusammensetzung enthaltend Levoleucovorin
CA2974953A1 (en) * 2015-01-27 2016-08-04 La Vita Compounding Pharmacy Stable 5-methyltetrahydrofolate formulations to moderate methylenetetrahydrofolate reductase associated polymorphisms
MX2021009084A (es) * 2019-01-31 2021-10-26 Scpharmaceuticals Inc Formulaciones farmaceuticas liquidas concentradas de furosemida y metodos para administrar las mismas.
CN112198302B (zh) * 2020-10-25 2022-12-16 中铁二局第一工程有限公司 一种细集料含泥量快速检测方法及测量工具
CN118059042A (zh) * 2024-04-17 2024-05-24 成都瑞尔医药科技有限公司 一种亚叶酸钙注射液及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2695860A (en) * 1952-04-29 1954-11-30 American Cyanamid Co Stabilized pteroyl solutions
US4071620A (en) * 1977-01-10 1978-01-31 American Home Products Corporation Stabilization of oxygen sensitive dose forms
WO1988004927A1 (en) * 1986-12-31 1988-07-14 Davirand, Inc. Compositions and formulations containing folic acid, method of treating tissue with folic acid and method for preparing compositions and formulations of folic acid

Also Published As

Publication number Publication date
EP0416232A2 (de) 1991-03-13
KR0159768B1 (ko) 1998-12-01
CA2023563C (en) 2000-02-22
JP3043381B2 (ja) 2000-05-22
AU6116590A (en) 1991-02-21
JPH0390026A (ja) 1991-04-16
PT95026B (pt) 1997-12-31
DE69021673T2 (de) 1996-05-02
AU628211B2 (en) 1992-09-10
EP0416232A3 (en) 1992-01-02
ES2076263T3 (es) 1995-11-01
KR910004194A (ko) 1991-03-28
CA2023563A1 (en) 1991-02-22
DE69021673D1 (de) 1995-09-21
GR3017143T3 (en) 1995-11-30
EP0416232B1 (de) 1995-08-16
DK0416232T3 (da) 1995-09-18
PT95026A (pt) 1991-04-18

Similar Documents

Publication Publication Date Title
ATE126438T1 (de) Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren.
DE68916731D1 (de) Morphin enthaltende Zusammensetzung.
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
DE122011000014I1 (de) Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium.
ATE47715T1 (de) Stabile salze von sam mit polyanionen.
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
DK0598770T3 (da) Pyrazinderivater samt fremstilling og anvendelse deraf
ATE65401T1 (de) Stabile, injizierbare loesungen von salzen von vincristin.
DE59202227D1 (de) Stabile Salze von 5,10-Methylentetrahydrofolsäure.
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
NO902488L (no) Karboplatinapreparat.
AR245591A1 (es) Una composicion oral estable, con propiedades antiplaca y antigingivales mejoradas.
ATE117313T1 (de) Stabile lösungen von rebeccamycinderivaten sowie deren herstellung.
DE59101404D1 (de) Topische Präparate.
DE69121058D1 (de) Salze von Glykosaminoglykanen mit Aminosäureester, ihre Herstellung sowie sie enthaltende pharmazeutische Zusammensetzungen
DE69000259D1 (de) Pharmazeutische zusammensetzung enthaltend 1-isopropyldihydrolysergsaeure.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time